Characteristics of Myeloma Patients
| Patient . | Stage* . | Status . | Monoclonal Ig . | % Plasma Cells in BM . | |
|---|---|---|---|---|---|
| . | . | . | Class . | Level (g/L) . | . |
| 1 | IIIA | Relapsed | IgGκ | 24.0 | 11.0 |
| progressive | |||||
| 2 | IIA | Stable | IgGκ | 18.0 | 21.0 |
| 3 | II | Progressive | IgGκ | 43.0 | 5.0 |
| 4 | II | Stable | IgGκ | 28.0 | 30.0 |
| 5 | III | Progressive | IgGκ | 15.0 | 18.0 |
| 6 | IIA | Presentation | IgGκ | 59.0 | 14.0 |
| 7 | IIIA | Progressive | IgGκ | 71.0 | 30.0 |
| 8 | IB | Presentation | IgAκ | 40.7 | 60.0 |
| 9 | III | Progressive | IgGκ | 48.0 | 30.0 |
| 10 | IIA | Progressive | IgGλ | 20.0 | 19.0 |
| 11 | I | Stable | IgGλ | 16.0 | 4.0 |
| 12 | III | Progressive | IgGλ | 60.0 | 5.0 |
| 13 | III | Progressive | IgGλ | 21.0 | 10.0 |
| 14 | I | Progressive | IgAλ | 3.0 | 1.8 |
| 15 | IIIA | Presentation | IgGλ | 79.0 | 50.0 |
| Patient . | Stage* . | Status . | Monoclonal Ig . | % Plasma Cells in BM . | |
|---|---|---|---|---|---|
| . | . | . | Class . | Level (g/L) . | . |
| 1 | IIIA | Relapsed | IgGκ | 24.0 | 11.0 |
| progressive | |||||
| 2 | IIA | Stable | IgGκ | 18.0 | 21.0 |
| 3 | II | Progressive | IgGκ | 43.0 | 5.0 |
| 4 | II | Stable | IgGκ | 28.0 | 30.0 |
| 5 | III | Progressive | IgGκ | 15.0 | 18.0 |
| 6 | IIA | Presentation | IgGκ | 59.0 | 14.0 |
| 7 | IIIA | Progressive | IgGκ | 71.0 | 30.0 |
| 8 | IB | Presentation | IgAκ | 40.7 | 60.0 |
| 9 | III | Progressive | IgGκ | 48.0 | 30.0 |
| 10 | IIA | Progressive | IgGλ | 20.0 | 19.0 |
| 11 | I | Stable | IgGλ | 16.0 | 4.0 |
| 12 | III | Progressive | IgGλ | 60.0 | 5.0 |
| 13 | III | Progressive | IgGλ | 21.0 | 10.0 |
| 14 | I | Progressive | IgAλ | 3.0 | 1.8 |
| 15 | IIIA | Presentation | IgGλ | 79.0 | 50.0 |
Durie and Salmon staging.